146 related articles for article (PubMed ID: 32339532)
1. RNA-based CRISPR-Mediated Loss-of-Function Mutagenesis in Human Pluripotent Stem Cells.
Leung AW; Broton C; Bogacheva MS; Xiao AZ; Garcia-Castro MI; Lou YR
J Mol Biol; 2020 Jun; 432(13):3956-3964. PubMed ID: 32339532
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-Mediated Mutagenesis of Human Pluripotent Stem Cells in Defined Xeno-Free E8 Medium.
Soh CL; Huangfu D
Methods Mol Biol; 2017; 1498():57-78. PubMed ID: 27709569
[TBL] [Abstract][Full Text] [Related]
3. TALEN- and CRISPR/Cas9-Mediated Gene Editing in Human Pluripotent Stem Cells Using Lipid-Based Transfection.
Hendriks WT; Jiang X; Daheron L; Cowan CA
Curr Protoc Stem Cell Biol; 2015 Aug; 34():5B.3.1-5B.3.25. PubMed ID: 26237572
[TBL] [Abstract][Full Text] [Related]
4. Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity.
Basila M; Kelley ML; Smith AVB
PLoS One; 2017; 12(11):e0188593. PubMed ID: 29176845
[TBL] [Abstract][Full Text] [Related]
5. [Efficient genome editing in human pluripotent stem cells through CRISPR/Cas9].
Liu GG; Li S; Wei YD; Zhang YX; Ding QR
Yi Chuan; 2015 Nov; 37(11):1167-73. PubMed ID: 26582531
[TBL] [Abstract][Full Text] [Related]
6. Design and Derivation of Multi-Reporter Pluripotent Stem Cell Lines via CRISPR/Cas9n-Mediated Homology-Directed Repair.
Dettmer R; Naujok O
Curr Protoc Stem Cell Biol; 2020 Sep; 54(1):e116. PubMed ID: 32628328
[TBL] [Abstract][Full Text] [Related]
7. Generating CRISPR-Cas9-Mediated Null Mutations and Screening Targeting Efficiency in Human Pluripotent Stem Cells.
Bower OJ; McCarthy A; Lea RA; Alanis-Lobato G; Zohren J; Gerri C; Turner JMA; Niakan KK
Curr Protoc; 2021 Aug; 1(8):e232. PubMed ID: 34432381
[TBL] [Abstract][Full Text] [Related]
8. CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs.
Coelho MA; De Braekeleer E; Firth M; Bista M; Lukasiak S; Cuomo ME; Taylor BJM
Nat Commun; 2020 Aug; 11(1):4132. PubMed ID: 32807781
[TBL] [Abstract][Full Text] [Related]
9. An Agrobacterium-delivered CRISPR/Cas9 system for high-frequency targeted mutagenesis in maize.
Char SN; Neelakandan AK; Nahampun H; Frame B; Main M; Spalding MH; Becraft PW; Meyers BC; Walbot V; Wang K; Yang B
Plant Biotechnol J; 2017 Feb; 15(2):257-268. PubMed ID: 27510362
[TBL] [Abstract][Full Text] [Related]
10. Genetic Modification in Human Pluripotent Stem Cells by Homologous Recombination and CRISPR/Cas9 System.
Xue H; Wu J; Li S; Rao MS; Liu Y
Methods Mol Biol; 2016; 1307():173-90. PubMed ID: 24615461
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-Directed Genome Editing of Cultured Cells.
Yang L; Yang JL; Byrne S; Pan J; Church GM
Curr Protoc Mol Biol; 2014 Jul; 107():31.1.1-31.1.17. PubMed ID: 24984853
[TBL] [Abstract][Full Text] [Related]
12. Targeted Mutations in the Mouse via Embryonic Stem Cells.
Gertsenstein M; Mianné J; Teboul L; Nutter LMJ
Methods Mol Biol; 2020; 2066():59-82. PubMed ID: 31512207
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9 Structures and Mechanisms.
Jiang F; Doudna JA
Annu Rev Biophys; 2017 May; 46():505-529. PubMed ID: 28375731
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of single guide RNA transcription for efficient CRISPR/Cas-based genomic engineering.
Ui-Tei K; Maruyama S; Nakano Y
Genome; 2017 Jun; 60(6):537-545. PubMed ID: 28177825
[TBL] [Abstract][Full Text] [Related]
15. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
Xu R; Wei P; Yang J
Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
[TBL] [Abstract][Full Text] [Related]
16. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-based Targeted Genome Editing for the Development of Monogenic Diseases Models with Human Pluripotent Stem Cells.
Gupta N; Susa K; Yoda Y; Bonventre JV; Valerius MT; Morizane R
Curr Protoc Stem Cell Biol; 2018 May; 45(1):e50. PubMed ID: 30040245
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
19. Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9.
Yumlu S; Stumm J; Bashir S; Dreyer AK; Lisowski P; Danner E; Kühn R
Methods; 2017 May; 121-122():29-44. PubMed ID: 28522326
[TBL] [Abstract][Full Text] [Related]
20. The iCRISPR platform for rapid genome editing in human pluripotent stem cells.
Zhu Z; González F; Huangfu D
Methods Enzymol; 2014; 546():215-50. PubMed ID: 25398343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
